Incyte's topical JAK inhibitor positive in Phase II
This article was originally published in Scrip
Executive Summary
Incyte Corporation's topical formulation of its lead JAK inhibitor, INCB18424, has met the primary endpoint of a Phase IIb trial for the treatment of psoriasis, showing a reduction in the scaling, thickness and erythema of lesions compared with placebo.